Dr. John H. Strickler, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 112
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Chicago, Pritzker School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME182451 -
Internal Medicine Physician
WA license ML20008301 -
Medical Oncology Physician
NC license 2009-00266
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 112
- Services billed
- 466
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 184 | 73 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 57 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 56 payments worth $69,998 in total to this clinician.
| AbbVie Inc. | $27,405 |
|---|---|
| Pfizer Inc. | $12,517 |
| Janssen Research & Development, LLC | $10,860 |
| Exelixis Inc. | $7,712 |
| E.r. Squibb & Sons, L.l.c. | $3,343 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,045 |
| Astellas Pharma Global Development | $1,741 |
| Taiho Oncology, Inc. | $1,724 |
| Consulting Fee | $48,712 |
|---|---|
| Travel and Lodging | $13,471 |
| Honoraria | $6,600 |
| Food and Beverage | $1,083 |
| Education | $67.00 |
| Compensation for services other than consulting (speaking, faculty) | $65.89 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to BERLIN, Germany · in-kind | $10,019 |
| Pfizer Inc. Dec 15, 2025 | Consulting Fee | $5,966 |
| Exelixis Inc. Dec 12, 2025 | Honoraria | $4,400 |
| AbbVie Inc. Mar 7, 2025 | Consulting Fee | $4,350 |
| AbbVie Inc. Nov 10, 2025 | Consulting Fee | $3,988 |
| AbbVie Inc. Nov 11, 2025 | Consulting Fee | $3,625 |
| E.r. Squibb & Sons, L.l.c. Oct 17, 2025 | Consulting Fee | $3,343 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee | $3,045 |
| Pfizer Inc. Nov 3, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $2,695 |
| AbbVie Inc. Jun 9, 2025 | Consulting Fee | $2,538 |
All 38 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Dec 23, 2025 | Consulting Fee | $2,025 |
| Pfizer Inc. Dec 15, 2025 | Consulting Fee | $5,966 |
| Exelixis Inc. Dec 12, 2025 | Honoraria | $4,400 |
| Exelixis Inc. Dec 12, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,200 |
| Exelixis Inc. Dec 11, 2025 | Travel and Lodging travel to New York, NY · in-kind | $514 |
| Exelixis Inc. Dec 11, 2025 | Travel and Lodging travel to New York, NY · in-kind | $345 |
| Exelixis Inc. Dec 11, 2025 | Travel and Lodging travel to New York, NY | $64.00 |
| Astellas Pharma Global Development Dec 5, 2025 | Consulting Fee Vyloy · Oncology | $1,741 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 19, 2025 | Consulting Fee | $702 |
| Janssen Research & Development, LLC Nov 17, 2025 | Consulting Fee | $2,025 |
| AbbVie Inc. Nov 11, 2025 | Consulting Fee | $3,625 |
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to BERLIN, Germany · in-kind | $10,019 |
| AbbVie Inc. Nov 10, 2025 | Consulting Fee | $3,988 |
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to BERLIN, Germany · in-kind | $1,440 |
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to BERLIN, Germany · in-kind | $200 |
| Pfizer Inc. Nov 3, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $2,695 |
| Pfizer Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $45.00 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee | $3,045 |
| E.r. Squibb & Sons, L.l.c. Oct 17, 2025 | Consulting Fee | $3,343 |
| Astellas Pharma Europe LTD Oct 17, 2025 | Travel and Lodging Vyloy · Oncology · travel to Berlin, Germany | $56.94 |
| Janssen Research & Development, LLC Sep 29, 2025 | Consulting Fee | $2,025 |
| Janssen Research & Development, LLC Aug 27, 2025 | Consulting Fee | $2,025 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 29, 2025 | Consulting Fee | $702 |
| Janssen Research & Development, LLC Jul 2, 2025 | Consulting Fee | $1,350 |
| Pfizer Inc. Jun 17, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $2,160 |
| Pfizer Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $20.89 |
| AbbVie Inc. Jun 9, 2025 | Consulting Fee | $2,538 |
| AbbVie Inc. Jun 6, 2025 | Consulting Fee | $57.97 |
| GlaxoSmithKline, LLC. Jun 2, 2025 | Education in-kind | $67.00 |
| Janssen Research & Development, LLC Apr 14, 2025 | Consulting Fee | $1,350 |
| AbbVie Inc. Mar 10, 2025 | Travel and Lodging travel to MORRISVILLE, NC · in-kind | $42.00 |
| AbbVie Inc. Mar 7, 2025 | Consulting Fee | $4,350 |
| Pfizer Inc. Mar 3, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $1,440 |
| AbbVie Inc. Mar 1, 2025 | Travel and Lodging travel to DORAL, FL · in-kind | $267 |
| AbbVie Inc. Mar 1, 2025 | Travel and Lodging travel to DORAL, FL · in-kind | $133 |
| AbbVie Inc. Feb 28, 2025 | Travel and Lodging travel to DORAL, FL · in-kind | $247 |
| AbbVie Inc. Feb 28, 2025 | Travel and Lodging travel to DORAL, FL · in-kind | $143 |
| Taiho Oncology, Inc. Feb 19, 2025 | Consulting Fee LONSURF · Oncology | $1,560 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 28 industry-funded studies in 2025, from 11 companies. The companies reported $4,058,488 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.…
Amgen Inc. - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie Inc. · Recruiting · NCT06084481 - Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer …
Amgen Inc. - A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Beone Medicines USA, Inc. · Active, not recruiting · NCT05609370 - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie Inc. · Active, not recruiting · NCT05029882 - MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06586515 - A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation a…
Amgen Inc. - An openlabel randomized phase 3 study of tucatinib in combination with trastuzumab and MFOLFOX6 versus MFOLFOX6 given with or without either cetuximab or bevacizumab as firstline treatment for subjects with HER2 metas…
Pfizer Inc. - EiH study with WRNinh in MSI dMMR advanced solid tumors
Roche Products Limited - A Phase 1,2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction GEJ, or Pancreatic Ductal AdEnocarcinomas of PT886,…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.